G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 27.2 PLN 3.82%
Market Cap: 35.9m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genomed SA
Total Liabilities & Equity Peer Comparison

Comparables:
M
MAB
R
RDG
B
BIO
U
URT
S
SVE

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł196.4m
CAGR 3-Years
-5%
CAGR 5-Years
11%
CAGR 10-Years
5%
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł799.1m
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-8%
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł291.7m
CAGR 3-Years
51%
CAGR 5-Years
27%
CAGR 10-Years
11%

See Also

What is Genomed SA's Total Liabilities & Equity?
Total Liabilities & Equity
12.1m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Total Liabilities & Equity amounts to 12.1m PLN.

What is Genomed SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
5%

Over the last year, the Total Liabilities & Equity growth was 17%. The average annual Total Liabilities & Equity growth rates for Genomed SA have been 7% over the past three years , 5% over the past five years .

Back to Top